atopic dermatitis
Conditions
Interventions
Placebo group:Oral supplementation of probiotic ingredients for 12 weeks
Bifidobacterium longum group:Oral supplementation of Bifidobacterium longum CCFM1029 for 12 weeks
Lactobacillus casei group:Oral supplementation of Lactobacillus casei CCFM1073 for 12 weeks
Sponsors
Women’s Hospital of Jiangnan University(Wuxi Maternity and Child Health Care Hospital)
Eligibility
Sex/Gender
All
Age
No minimum to 3 Years
Inclusion criteria
Inclusion criteria: Individuals must meet all of the following criteria: (1) infants and young children < 36 months of age; (2) Diagnosed with AD according to Williams criteria; (3) The dermatologist evaluated atopic dermatitis with a SCORAD score =50 (mild to moderate); (4) Parents or guardians sign informed consent.
Exclusion criteria
Exclusion criteria: Individuals who meet any of the following criteria will be excluded from this trial: (1) children with immunodeficiency diseases and immunocompromised children; (2) The child has used systemic immunosuppressants or glucocorticoids or antibiotics in the past 1 month; (3) the child has taken probiotic-related products in the past 2 weeks, or is currently taking probiotics, and does not want to stop; (4) Parents or guardians refuse to sign the informed consent; (5) Children who have participated in a drug study within the past 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SCORing of Atopic Dermatitis;Eczema area and severity index; | — |
Secondary
| Measure | Time frame |
|---|---|
| Investigator Global Assessment;body surface area;Infants’ Dermatitis Quality of Life Index;Dermatitis Family Index;worst scratch and itch Numerical Rating;Sleep quality Numerical Rating;eosinophil count;Total IgE;IL-4;TARC;lymphocyte subsets;drug therapy;Incidence of allergic disease; | — |
Countries
China
Contacts
Public ContactRenqiang Yu
Women’s Hospital of Jiangnan University(Wuxi Maternity and Child Health Care Hospital)
Outcome results
None listed